Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

53 results about "Diagnosis of schizophrenia" patented technology

The diagnosis of schizophrenia is based on criteria in either the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, version DSM-5, or the World Health Organization's International Statistical Classification of Diseases and Related Health Problems, the ICD-10. Clinical assessment is performed by a mental health professional based on observed behavior, reported experiences, and reports of others familiar with the person. Symptoms associated with schizophrenia occur along a continuum in the population and must reach a certain severity and level of impairment before a diagnosis is made.

Method of diagnosing integration dysfunction syndrome using blood

An object of the present invention is. to provide an objective method for diagnosis of schizophrenia using gene expression in mononuclear cells of peripheral blood as an index, and this invention provide a method for diagnosing whether a test subject suffers from schizophrenia or not. The method according to this invention is a method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing nucleic acid from said subject, measuring the content of at least one nucleic acid selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, and determining alteration of the quantified level(s) of the gene(s) in said test subject is statistically significant in comparison with the quantified level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy subjects or schizophrenic patients, thereby diagnosing whether said subject is suffering from schizophrenia or not.
Owner:JAPAN SCI & TECH CORP +1

Brain network classification method combining node attributes and multi-level topology

The invention discloses a brain network classification method combining node attributes and multi-level topology, and the method comprises the following steps: S1, obtaining functional magnetic resonance brain image data, and carrying out the preprocessing; S2, based on the preprocessed data, generating a whole-brain network function connection matrix by using an automatic anatomical marking template, and constructing an unbiased brain network by using a Kruskal algorithm and taking DMN as a region of interest; S3, extracting brain region node betweenness from the unbiased brain network to serve as local attribute features, and extracting brain region features with inter-group significant differences by using a double-sample t test method; S4, extracting multi-level topological features on the unpartial brain network by using sub-network kernels, generating a sub-network kernel matrix, and extracting optimal topological features by using a kernel principal component analysis method. According to the method, the classification performance is remarkably improved, an abnormal brain area can be found, multi-level topological characteristics of brain area nodes can be captured, and the method has important significance in clinical auxiliary diagnosis of schizophrenia.
Owner:TAIYUAN UNIV OF TECH

Schizophrenia early diagnosis model based on face expression recognition magnetic resonance imaging and application thereof

The invention relates to the technical field of early diagnosis of schizophrenia, in particular to a schizophrenia early diagnosis model based on face expression recognition magnetic resonance imagingand application thereof. The method includes: obtaining the brain imaging data under the magnetic resonance as the training data of the model; extracting features from training data; screening the extracted features; establishing an early diagnosis model of schizophrenia by using the screened features and supervised machine learning method for model training. Schizophrenia is a serious psychiatric disease.Patients with schizophrenia suffer from severe social dysfunction, and those with severe schizophrenia often have impulse, self-injury and wounding behavior.Improving the recognition rate ofschizophrenia is helpful to postpone the social dysfunction of schizophrenia patients and lighten the burden of family and society. The invention successfully constructs a multidimensional early diagnosis model of schizophrenia through feature screening according to different dimensional indexes of brain function and brain structure, and improves the recognition rate and diagnosis rate of schizophrenia patients.
Owner:SHANGHAI TONGJI HOSPITAL

Methods and kits for diagnosis of schizophrenia

The present invention provides methods and kits for the diagnosis of schizophrenia, which employ mitochondrial complex I as a peripheral biological marker for schizophrenia. In one embodiment, the present invention provides a method for diagnosing schizophrenia in a subject by determining the level of activity of a mitochondrial complex I enzyme in a sample obtained from the subject, and comparing the level of activity in the sample with a normative value of mitochondrial complex I enzyme activity, wherein an altered level of activity of mitochondrial complex I enzyme in the sample compared with the normative value is indicative of the subject having schizophrenia. In another embodiment, the present invention provides a method for diagnosing schizophrenia in a subject by determining the level of m-RNA or protein of mitochondrial complex I in a sample obtained from the subject, and comparing the level m-RNA or protein of mitochondrial complex I in the sample with a normative value of mitochondrial complex I m-RNA or protein, wherein an altered level of mitochondrial complex I m-RNA or protein in the sample compared with the normative value is indicative of the subject having schizophrenia. Kits for diagnosing schizophrenia using the methods of the present invention are also disclosed.
Owner:TECHNION RES & DEV FOUND LTD

Exosome assay for depression and psychosis and methods and agents for treating depression, psychosis and schizophrenia

The present disclosure relates to exosomal complement mediators, cytokines, and mitochondrial electron transport biomarkers and diagnostic and prognostic methods for depression, psychosis and schizophrenia. The disclosure also provides compositions for detecting exosomal complement mediators, cytokines, and mitochondrial electron transport biomarkers in biological samples as well as compositions and methods useful for treating depression, psychosis and schizophrenia.
Owner:GOETZL EDWARD J
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products